8.42
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Eyepoint Pharmaceuticals Inc Borsa (EYPT) Ultime notizie
Forecasting The Future: 4 Analyst Projections For EyePoint Pharmaceuticals - Benzinga
RBC Capital Initiates Coverage on EyePoint Pharmaceuticals (EYPT - GuruFocus
EyePoint Pharmaceuticals (EYPT) Poised for Success with Positive Outlook | EYPT Stock News - GuruFocus
RBC Capital Initiates EyePoint Pharmaceuticals at Outperform With $28 Price Target - MarketScreener
After Leaping 47% EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar - simplywall.st
EyePoint (EYPT) Grants Stock Options to New Employees as Inducement | EYPT Stock News - GuruFocus
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 563 - GuruFocus
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - EyePoint Pharmaceuticals
EyePoint Awards 12,500 Shares in Stock Options to Three New Hires at $9.03 Per Share - Stock Titan
(EYPT) Trading Report - news.stocktradersdaily.com
EyePoint Stock: Retaining My 'Risky Buy' CallPivotal Data Due Early 2026 (NASDAQ:EYPT) - Seeking Alpha
Cantor Fitzgerald Weighs in on EYPT FY2026 Earnings - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of “Buy” from Analysts - Defense World
EyePoint at Goldman Sachs Healthcare Conference: Sustained-Release Vision By Investing.com - Investing.com Canada
Breakout Momentum Plays You May Not Know About - Investing.com
Squarepoint Ops LLC Has $302,000 Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Ameriprise Financial Inc. Grows Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Nuveen Asset Management LLC Raises Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
ProShare Advisors LLC Buys 8,981 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
(EYPT) Investment Report - news.stocktradersdaily.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $276,000 Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum - MSN
Millennium Management LLC Buys New Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
EyePoint advances with Duravyu Phase III trial - Yahoo
H.C. Wainwright maintains Buy on EyePoint with $22 target - Investing.com India
H.C. Wainwright maintains Buy on EyePoint with $22 target By Investing.com - Investing.com Nigeria
EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders are up 29% this past week, but still in the red over the last year - simplywall.st
EyePoint Pharmaceuticals’ (EYPT) Buy Rating Reaffirmed at HC Wainwright - Defense World
Biggest Companies on Nasdaq EyePoint Pharmaceuticals Insights by Kalkine - Kalkine Media
Analyst Expectations For EyePoint Pharmaceuticals's Future - Benzinga
EyePoint Pharmaceuticals (EYPT) Reiterates Buy Rating with $22 P - GuruFocus
EyePoint Pharmaceuticals (EYPT) Reiterates Buy Rating with $22 Price Target | EYPT Stock News - GuruFocus
Bank of America Corp DE Acquires 145,065 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
EyePoint Announces Participation at Upcoming Investor Conferences - The Manila Times
EyePoint Secures Triple Conference Spotlight: Goldman Sachs, Jefferies, and Guggenheim Healthcare Events - Stock Titan
EYPTEyepoint Pharmac Latest Stock News & Market Updates - Stock Titan
EyePoint at Stifel Forum: Strategic Advances in Ophthalmology By Investing.com - Investing.com Canada
JPMorgan maintains EyePoint stock Overweight with $26 target - Investing.com India
JPMorgan maintains EyePoint stock Overweight with $26 target By Investing.com - Investing.com UK
Eyepoint Completes Enrollment In Pivotal Phase 3 Lugano Trial Of Duravy For Treatment Of Wet Age-Related Macular Degeneration - marketscreener.com
EyePoint (EYPT) Surpasses Enrollment Goal in Key Phase 3 Trial | - GuruFocus
EyePoint Completes Enrollment for DURAVYU Phase 3 Trial - TipRanks
EyePoint Pharmaceuticals Reports Rapid Enrollment Progress in Phase 3 LUGANO Trial of DURAVYU™ for Wet AMD Treatment - Nasdaq
EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration - The Manila Times
Clinical Trial Milestone: EyePoint's Revolutionary 6-Month Eye Treatment Completes Phase 3 Enrollment - Stock Titan
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors - The Globe and Mail
Deutsche Bank AG Has $1.59 Million Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
BNP Paribas Financial Markets Purchases New Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
(EYPT) Trading Signals - news.stocktradersdaily.com
Northern Trust Corp Has $4.79 Million Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Insider Buying: Karen Zaderej Acquires Additional Shares of EyeP - GuruFocus
Insider Buying: Karen Zaderej Acquires Additional Shares of EyePoint Pharmaceuticals Inc (EYPT) - GuruFocus
Dimensional Fund Advisors LP Sells 2,063 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
The Manufacturers Life Insurance Company Boosts Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of “Buy” from Brokerages - Defense World
EyePoint Pharmaceuticals (EYPT) Target Price Lowered by Mizuho Analyst | EYPT Stock News - GuruFocus
EyePoint (EYPT) Faces Price Target Reduction by Mizuho | EYPT St - GuruFocus
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):